Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of potent, selective, CNS-targeted inverse agonists of the ghrelin receptor.
McClure KF, Jackson M, Cameron KO, Kung DW, Perry DA, Orr ST, Zhang Y, Kohrt J, Tu M, Gao H, Fernando D, Jones R, Erasga N, Wang G, Polivkova J, Jiao W, Swartz R, Ueno H, Bhattacharya SK, Stock IA, Varma S, Bagdasarian V, Perez S, Kelly-Sullivan D, Wang R, Kong J, Cornelius P, Michael L, Lee E, Janssen A, Steyn SJ, Lapham K, Goosen T. McClure KF, et al. Among authors: kelly sullivan d. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5410-4. doi: 10.1016/j.bmcl.2013.07.044. Epub 2013 Jul 30. Bioorg Med Chem Lett. 2013. PMID: 23953189
New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.
Carpino PA, Griffith DA, Sakya S, Dow RL, Black SC, Hadcock JR, Iredale PA, Scott DO, Fichtner MW, Rose CR, Day R, Dibrino J, Butler M, Debartolo DB, Dutcher D, Gautreau D, Lizano JS, O'connor RE, Sands MA, Kelly-Sullivan D, Ward KM. Carpino PA, et al. Among authors: kelly sullivan d. Bioorg Med Chem Lett. 2006 Feb;16(3):731-6. doi: 10.1016/j.bmcl.2005.10.019. Epub 2005 Nov 2. Bioorg Med Chem Lett. 2006. PMID: 16263283
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
Hadcock JR, Griffith DA, Iredale PA, Carpino PA, Dow RL, Black SC, O'Connor R, Gautreau D, Lizano JS, Ward K, Hargrove DM, Kelly-Sullivan D, Scott DO. Hadcock JR, et al. Among authors: kelly sullivan d. Biochem Biophys Res Commun. 2010 Apr 2;394(2):366-71. doi: 10.1016/j.bbrc.2010.03.015. Epub 2010 Mar 6. Biochem Biophys Res Commun. 2010. PMID: 20211605
Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.
Hadcock JR, Carpino PA, Iredale PA, Dow RL, Gautreau D, Thiede L, Kelly-Sullivan D, Lizano JS, Liu X, Van Deusen J, Ward KM, O'Connor RE, Black SC, Griffith DA, Scott DO. Hadcock JR, et al. Among authors: kelly sullivan d. BMC Pharmacol. 2010 Aug 16;10:9. doi: 10.1186/1471-2210-10-9. BMC Pharmacol. 2010. PMID: 20712891 Free PMC article.
Pharmacological characterization of a small molecule inhibitor of c-Jun kinase.
Cho H, Black SC, Looper D, Shi M, Kelly-Sullivan D, Timofeevski S, Siegel K, Yu XH, McDonnell SR, Chen P, Yie J, Ogilvie KM, Fraser J, Briscoe CP. Cho H, et al. Among authors: kelly sullivan d. Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1142-51. doi: 10.1152/ajpendo.90298.2008. Epub 2008 Aug 26. Am J Physiol Endocrinol Metab. 2008. PMID: 18728225 Free article.
Identification of a PCSK9-LDLR disruptor peptide with in vivo function.
Brousseau ME, Clairmont KB, Spraggon G, Flyer AN, Golosov AA, Grosche P, Amin J, Andre J, Burdick D, Caplan S, Chen G, Chopra R, Ames L, Dubiel D, Fan L, Gattlen R, Kelly-Sullivan D, Koch AW, Lewis I, Li J, Liu E, Lubicka D, Marzinzik A, Nakajima K, Nettleton D, Ottl J, Pan M, Patel T, Perry L, Pickett S, Poirier J, Reid PC, Pelle X, Seepersaud M, Subramanian V, Vera V, Xu M, Yang L, Yang Q, Yu J, Zhu G, Monovich LG. Brousseau ME, et al. Among authors: kelly sullivan d. Cell Chem Biol. 2022 Feb 17;29(2):249-258.e5. doi: 10.1016/j.chembiol.2021.08.012. Epub 2021 Sep 20. Cell Chem Biol. 2022. PMID: 34547225 Free article.
12 results